Compare OCFC & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCFC | TYRA |
|---|---|---|
| Founded | 1902 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2021 |
| Metric | OCFC | TYRA |
|---|---|---|
| Price | $18.56 | $32.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $21.33 | ★ $44.63 |
| AVG Volume (30 Days) | 571.7K | ★ 740.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.43% | N/A |
| EPS Growth | N/A | ★ 6.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $46.71 | N/A |
| Revenue Next Year | $21.25 | N/A |
| P/E Ratio | $16.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.29 | $6.42 |
| 52 Week High | $20.61 | $35.71 |
| Indicator | OCFC | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 57.45 |
| Support Level | $17.24 | $26.14 |
| Resistance Level | $19.11 | N/A |
| Average True Range (ATR) | 0.61 | 2.63 |
| MACD | -0.13 | 0.13 |
| Stochastic Oscillator | 40.68 | 71.05 |
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.